Following a surge in second-quarter 2026 sales, TG Therapeutics raised its 2026 worldwide sales outlook to approximately $950 million. The focus is on whether the commercial rollout of BRIUMVI can support growth without weighing on margins.
TG Therapeutics' investment story is supported by expanding sales of BRIUMVI, its central multiple sclerosis treatment, and improving prospects for corresponding sales growth. Recent results support the sales outlook, while fluctuations in profitability and pricing and reimbursement risks have been identified as near-term concerns.
On 3 August 2026, the company raised its full-year 2026 worldwide sales outlook to approximately $950 million. Together with a solid first-half sales run rate, this has made the key question whether the commercial rollout of BRIUMVI can support growth without weighing on margins.
However, payer resistance to high-cost MS treatments could have an impact, and the caveat remains that this does not eliminate single-product or payer risks.
Some analysts expect sales of approximately $2 billion and earnings of nearly $687.2 million by 2029, potentially prompting renewed examination of BRIUMVI's market expansion and pricing pressure.
A final assessment will require monitoring future earnings trends and developments in pricing discussions with payers.